Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI). It has Long-Acting Beta2 Agonist collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INVA
CUSIP88338T10
Phone650-238-9600
Debt
Debt-to-Equity Ratio-2.28
Current Ratio27.89
Quick Ratio27.89
Price-To-Earnings
Trailing P/E Ratio12.09
Forward P/E Ratio6.49
P/E GrowthN/A
Sales & Book Value
Annual Sales$217.22 million
Price / Sales6.63
Cash Flow$1.4573 per share
Price / Cash9.71
Book Value($2.38) per share
Price / Book-5.95
Profitability
EPS (Most Recent Fiscal Year)$1.17
Net Income$134.14 million
Net Margins64.11%
Return on Equity-63.57%
Return on Assets44.05%
Miscellaneous
Employees12
Outstanding Shares101,820,000
Innoviva (NASDAQ:INVA) Frequently Asked Questions
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "INVA."
How were Innoviva's earnings last quarter?
Innoviva Inc (NASDAQ:INVA) released its quarterly earnings results on Thursday, April, 26th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.50 by $0.23. The biotechnology company earned $52.40 million during the quarter, compared to analysts' expectations of $71.84 million. Innoviva had a negative return on equity of 63.57% and a net margin of 64.11%. The business's quarterly revenue was up 29.4% on a year-over-year basis. During the same quarter last year, the business earned $0.19 earnings per share. View Innoviva's Earnings History.
When is Innoviva's next earnings date?
What price target have analysts set for INVA?
6 analysts have issued 12 month price targets for Innoviva's shares. Their forecasts range from $8.00 to $16.00. On average, they anticipate Innoviva's stock price to reach $13.20 in the next year. View Analyst Ratings for Innoviva.
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Loxo Oncology (LOXO), FibroGen (FGEN), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Taro Pharmaceutical Industries (TARO), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Madrigal Pharmaceuticals (MDGL) and HUTCHISON CHINA/S (HCM).
Who are Innoviva's key executives?
Innoviva's management team includes the folowing people:
- Mr. Eric d'Esparbes, Interim Principal Exec. Officer, Sr. VP & CFO (Age 50)
- Dr. Theodore J. Witek Jr., Sr. VP & Chief Scientific Officer (Age 60)
- Mr. George B. Abercrombie M.B.A., R.Ph., RPh, MBA, Sr. VP & Chief Commercial Officer (Age 63)
- Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
- Dr. Kevin Kwok, Head of Talent Acquisition & Strategy
Has Innoviva been receiving favorable news coverage?
Media headlines about INVA stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Innoviva earned a news impact score of 0.08 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 47.97 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Innoviva's major shareholders?
Innoviva's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.68%), Dimensional Fund Advisors LP (1.69%), First Eagle Investment Management LLC (1.34%), Northern Trust Corp (1.01%), UBS Group AG (0.70%) and Victory Capital Management Inc. (0.63%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.
Which institutional investors are selling Innoviva stock?
INVA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., JPMorgan Chase & Co., Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Smith Asset Management Group LP, Systematic Financial Management LP, Camarda Financial Advisors LLC and Northern Trust Corp. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie and Michael W Aguiar. View Insider Buying and Selling for Innoviva.
Which institutional investors are buying Innoviva stock?
INVA stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Dimensional Fund Advisors LP, PNC Financial Services Group Inc., WINTON GROUP Ltd, Millennium Management LLC, Hsbc Holdings PLC, Algert Global LLC and Hussman Strategic Advisors Inc.. View Insider Buying and Selling for Innoviva.
How do I buy shares of Innoviva?
Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innoviva's stock price today?
One share of INVA stock can currently be purchased for approximately $14.15.
How big of a company is Innoviva?
Innoviva has a market capitalization of $1.48 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe.
How can I contact Innoviva?
Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]
MarketBeat Community Rating for Innoviva (INVA)
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
